Targeted Therapies & Future
Directives: RNAi Drug Delivery Market
According to Inkwood Research, the global RNA interference (RNAi) drug delivery market is expected to grow at a CAGR of 22.24% over the forecast period 2024–2032. Innovations in pharmaceuticals have propelled RNA interference (RNAi) drug delivery to the forefront of oncology treatment.
RNAi utilizes the body’s molecular mechanisms to silence disease-causing genes, offering precise therapeutic interventions with minimal side effects. This advancement has elevated significant progress in nanoparticle technologies, substantially enhancing drug delivery efficacy. Nanoparticlebased RNAi therapies allow for targeted delivery to tumor sites while minimizing systemic side effects.
Leading players like Pfizer (Germany) are pioneering nanoparticle-based RNAi therapies, focusing on advanced cancer treatments. These innovations, in turn, reflect a commitment to integrating modern research with industrial expertise, revolutionizing cancer therapy strategies globally.
Request a FREE sample of the RNAi Drug Delivery Market
RNAi Drug Delivery Market: Catalysts for Pharma Innovations
RNA interference (RNAi) was first discovered and described in 1998 by Andrew Fire and Craig Mello, leading to their Nobel Prize in Physiology in 2006. Their pioneering research demonstrated that double-stranded RNA (dsRNA) could silence specific genes by interfering with genetic expression.
This breakthrough laid the foundation for RNAi to emerge as a powerful tool in molecular biology and potential therapeutic applications.
Initially, RNA therapies focused on rare diseases but gained crucial momentum with mRNA vaccines during the COVID-19 pandemic, validating RNA technologies globally. This success spurred substantial investment and broadened development efforts into diverse therapeutic areas like neurology and metabolic disorders.
The evolution of RNA-based therapeutics has been intricately linked with innovations in drug delivery systems. Early on, cationic liposomes were employed to form protective complexes with mRNA, shielding it from degradation.
Liposome nanoparticles (LNPs) further emerged as sophisticated carriers, featuring lipid bilayer shells encapsulating mRNA payloads. LNPs have demonstrated safety and efficacy in delivering RNA therapeutics, facilitating robust immune responses and enabling local or systemic protein expression.
Furthermore, polymers like polyethyleneimine (PEI) and poly-amido-amine (PAA) are investigated for mRNA delivery, forming nanoparticles to improve cellular uptake and intracellular delivery efficiency.
In essence, a meta-analysis of biopharma intelligence databases shows substantial trends. It includes commercial sales, investments, and the scope of preclinical and clinical RNA programs over the years.
Read on to discover the substantial growth in the RNA-based pharmaceuticals sphere—
By 2022, the market capitalization of RNA-based therapies has surpassed $0.1 trillion, marking it as one of the fastest-growing segments in modern medicine.
The RNA-based companies’ market cap surged from $3 billion in 2012 to $228 billion in 2021
Products like nusinersen, an ASO treatment for spinal muscular atrophy, achieved peak sales of $2.1 billion in 2019
Similarly, inclisiran, the first siRNA approved for treating dyslipidemia, is projected to reach $2.7 billion in sales by 2028 (Source)
As a result, RNA therapies are expanding, pushed by technological advancements and increasing confidence in their competence across a wide range of medical applications.
Click here to get more insights about the Global RNAi Drug Delivery Market
From Oncogenes to Angiogenesis: RNA Interference in Cancer Research
RNA interference (RNAi) technology has revolutionized cancer research by offering a powerful tool to study and potentially treat various types of cancers. It operates through the silencing of specific genes implicated in tumorigenesis and metastasis.
One of the earliest applications of RNAi in cancer research was the targeting of oncogenes like K-Ras, which play critical roles in promoting tumor growth. By suppressing the expression of oncogenes such as Bcl-2, CDK-2, Mdm-2, PKC-α, TGF-β1, H-Ras, VEGF, and GFP, RNAi has shown efficacy in inhibiting cancer cell proliferation.
RNA drug interference has been used to target viral oncogenes in virally induced cancers, such as cervical cancer (HPV) and hepatocellular carcinoma (HBV), offering potential therapeutic avenues.
Additionally, RNAi studies on tumor suppressor genes like Rb have elucidated their roles in cancer progression through pathways like dE2F/dDP/RBF.
This drug interference has also been instrumental in studying DNA repair mechanisms by targeting genes such as Rad51, which is crucial for preventing tumor formation. It has identified nucleases involved in chromosomal DNA degradation and explored checkpoint responses by targeting genes like ATR
In the context of cancer invasion and metastasis, RNAi-mediated inhibition of genes such as RECK and CXCR4 has demonstrated potential in regulating tumor cell migration and invasion. RNAi has further targeted angiogenesis-related proteins like VEGF and HIF, shedding light on their roles and potential as therapeutic targets. Moreover, RNAi is pivotal in studying anti-apoptotic genes like livin, Bcl-2, and xIAP, enhancing cancer cell sensitivity to traditional treatments.
In this regard, according to Inkwood Research, oncology was the major application in the global RNA interference (RNAi) drug delivery market in 2023.
Kindly click here to view the LinkedIn post related to this market
Nanoparticle Formulations in RNAi Drug Delivery Industry
Nanoparticle technology serves as versatile drug carriers that can be customized to overcome the limitations of traditional delivery systems. The technology enables precise control over the design and construction of drugs, influencing their size and shape.
By conjugating therapeutic agents, nanoscale methods create adaptable biocomposites that offer advantages in drug delivery and imaging. Intracellular targeting further aims to deliver drugs to specific sites within cells, such as tissues, organelles, or compartments.
Market Position: As per Inkwood Research, nanoparticle drug delivery was the largest technology in the global RNA interference (RNAi) drug delivery market in 2023.
Moving ahead, solid, lipid and polymer-based nanoparticle delivery systems are widely used in pharmaceutical and biomedical industries. Leading pharmaceutical and biomedical companies extensively utilize these drug delivery systems to enhance therapeutic potency and targeted drug delivery.
Explore how top pharmaceutical companies utilize nanoparticle-based drug delivery to advance targeted therapies:
Pfizer: Pfizer employs nanoparticle technology in products like Abraxane for cancer therapies. It enhances chemotherapy delivery directly to tumors while reducing systemic side effects.
Merck: Merck utilizes nanoparticles in Gardasil for vaccines and gene therapies, improving vaccine efficacy and enabling targeted delivery of genetic materials.
Johnson & Johnson: Johnson & Johnson applies polymer-based nanoparticles in products like Risperdal Consta for diseases like schizophrenia, improving drug stability and targeted delivery.
Novartis: Novartis uses lipid-based technologies in products like Kisqali for breast cancer treatment, improving drug solubility and extending circulation times.
Developments in nanoparticle-based drug delivery by these companies lead to advancements in their product offerings, driving precision medicine and personalized therapies globally. Hence, this progress positions them as leaders in cutting-edge healthcare solutions.
As advancements in RNAi drug delivery accelerate, there is a rising demand for precise and effective therapeutic solutions. With increasing research and investment in innovative technologies, the RNA interference (RNAi) drug delivery market is estimated to experience developing growth during the forecast period.
Explore the market insights in this YouTube video by clicking here
Can’t find what you’re looking for? Talk to an expert NOW!
FAQs:
1. Which diseases are targeted by RNAi drug delivery therapies?
A: RNAi therapies target a wide range of diseases, including genetic disorders, viral infections, neurodegenerative diseases, and various types of cancer. These therapies aim to intervene at the genetic level to treat underlying causes of disease.
2. What are the current challenges in RNAi drug delivery development?
A: The challenges in RNAi drug delivery include optimizing the delivery of RNA molecules to specific tissues, mitigating immune responses to synthetic RNA, and ensuring their safety and efficacy in clinical settings. Ongoing research focuses on refining delivery systems to effectively address these hurdles.